Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab open-label extension in active axial spondyloarthritis
NL-OMON55001Phase 3Not yet recruiting
- Sponsor
- UCB
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bimekizumab in axial spondyloarthritis (axSpA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA), sponsored by UCB. Primary endpoints: Treatment-emergent adverse events, Serious adverse events and 1 more. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
bimekizumab
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on NL-OMON55001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55001.